CHEVALLARD DANIEL R. (Chief Financial Officer) purchased 68.9% of their position (2.20K shares) of LENZ THERAPEUTICS, INC. on the open market
Open‑market purchase worth $50.0K — a major conviction buy. The strongest form of insider conviction signal.
P · 2 purchases
Filed: 11/7/2025ACC: 0001815776-25-000072
Officer· Chief Financial Officer
Since Mar 2024
+2.20K
Net shares
Net buyer
$50.0K
Total acquired
2
Open market trades
2B · 0S
2
Total transactions
2.20K acquired
Non-Derivative Transactions2
Common Stock
Direct
Shares
+20.00
Price / share
$22.71
Trade value
$454.20
% of position
0.6%
11/7/2025
3.19K→3.21K
Common Stock
Direct
Shares
+2.18K
Price / share
$22.76
Trade value
$49.56K
% of position
67.9%
11/7/2025
3.21K→5.39K
Total
Net shares
+2.20K
Net value
$50.02K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 11/7/2025 | P · Purchase | +20.00 | $22.71 | $454.20 | 0.6% | 3.19K | 3.21K |
| Common Stock Direct | 11/7/2025 | P · Purchase | +2.18K | $22.76 | $49.56K | 67.9% | 3.21K | 5.39K |
| Total | +2.20K | $50.02K | ||||||
Derivative Transactions0
No derivative transactions reported